On April 23, 2020 Cellesce reported that it has appointed Paul Jenkins as its CEO (Press release, Cellesce, JUL 23, 2020, View Source [SID1234562285]). Paul is a seasoned business development and senior management executive in the Life Science sector . He has amassed a wealth of deal-making and investment experience across a variety of therapeutic areas. Paul’s previous roles include VP Business Development at Catalent, CEO at Adjuvantix, and VP Business Development at West Pharmaceutical Services. Paul is also a strategic advisor to Yorkshire Cancer Research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Paul obtained his PhD in Immunology and Vaccine Design from Plymouth University and attended the London Business School’s ‘Accelerated Development Programme.’
"We are delighted to have secured Paul as our CEO following a period as a consultant and Interim CEO," said John Allbrook, Non-Executive Chairman of Cellesce. "His background and experience in the industry, particularly with early-stage biotech companies, is particularly welcome as we begin to commercialise our organoid technology. Paul’s appointment adds credibility to the fast-developing realisation that organoids have an important role to play in the drug discovery arena and other significant application areas."
"I am excited to be joining Cellesce at this pivotal time in the company’s development. Organoid biology is playing an ever more important role in helping large Pharma to reduce the attrition rate in their drug development programs and Cellesce’s expertise and technology are well placed to drive their adoption faster," said Paul Jenkins.
Organoids are three-dimensional (3D) stem cell cultures that can self-organise into ex vivo ‘mini-organs.’ They facilitate the study of tumour pathology to enable cancer drug discovery. Organoids are closer to in vivo tumours than more conventional 2D cell line cultures and can provide more relevant pharmacological responses to drugs and antibodies. By using organoids in drug discovery screening assays, scientists can identify active compounds for further progression earlier in the drug discovery process and weed out less attractive compounds before incurring higher downstream costs.